Personalized Medicine | Targeted Destruction of Cancer Cells | Oral GCSF | Oral Interferon |  Mucosal Cancer Vaccine
 

Mucosal Cancer Vaccines

Target therapy for: Mucosal surface cancers, such as gastric cancer, via a convenient oral dosage form.  Opportunity of vaccinating against infectious agents that induce cancers on mucosal surfaces (such as colorectal, cervical or lung cancer).

A programme for targeting infectious agents causing cancer, such as:

  • Broad-spectrum cancer targeting oncogene mutations caused by bacteria e.g. Mycoplasma hyorhinis, p37 infection
  • Vaccines against infectious agents implicated in inducing specific cancers on mucosal surfaces:
    • Helicobacter pylori causing gastric cancer
    • HPV causing cervical cancer
    • Streptococcus bovis causing colorectal cancer
    • Chlamydia pneumoniae causing lung cancer
    • Mycoplasma hyorhinis causing renal cell carcinoma
    • Salmonella typhi causing gallbladder cancer
    • Hepatitis causing liver cancer
    • EBV causing lymphoma

Our Approach:

  • Vaccination via a convenient ORAL dosage form using in-licensed Vaxcine(tm) technology
  • Stimulating the body’s own natural immune response via the Peyer’s patches thereby avoiding side-effects
  • This mucosal pathway is not readily accessed via injectable vaccines
  • A mucosal vaccine can be therapeutic as well as preventative
  • Other adjuvents and carriers have generally had tox issues e.g. Viral vectors

Stage of development: Vaccine carrier developed, validated in infectious disease applications